Search results
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
Motley Fool via Yahoo Finance· 2 hours agoPfizer Pfizer (NYSE: PFE) stock has been on a downward trajectory for nearly two and a half years....
The Motley Fool: Pfizer offers a pfat 6.4% dividend
Dallas Morning News· 2 hours agoShares of Pfizer were recently down more than 35% over the past year — in part because the market’s enthusiasm for its COVID-19 vaccine
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Reuters via Yahoo Finance· 3 days ago(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing...
RFK Jr. repeats debunked vaccine claims in interview with Bill Maher
Salon.com· 21 hours agoPresidential hopeful Robert F. Kennedy Jr. made an appearance on “Real Time with Bill Maher” on...
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
KFGO· 5 days agoBy Sam Tobin LONDON (Reuters) - Pfizer and BioNTech asked a London court to revoke rival Moderna's...
Bill Maher Batters His Buddy RFK Jr. Over Anti-Vax Claims
The Daily Beast via Yahoo News· 20 hours agoF. Kennedy Jr. to task on Friday’s episode of Real Time with Bill Maher, over his and his running...
Moderna, Pfizer/BioNTech set for UK court clash over COVID jab patents
Medical Xpress· 5 days agoA row between pharmaceutical firms Moderna and Pfizer/BioNTech comes to court in London on Tuesday...
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown -...
Benzinga· 5 days agoModerna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London...
New studies point to safety of COVID vaccines, but leave questions unanswered
KARE 11 Minneapolis-St. Paul· 3 days ago“I felt like I was dying,” said Norkus. Two days following a booster dose of the Pfizer COVID-19 ...
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 4 days agoPfizer stock is trading near an 11-year low as the drugmaker looks for its next big break after...